Cipla gets DCGI approval to sell Covid-19 drug favipiravir in India


Cipla Ltd has received Indian regulatory approval to sell anti-viral drug favipiravir to treat Covid-19, the drugmaker said on Friday, as coronavirus infections in the world's third worst-hit nation show no sign of abating.

The Drug Controller General of India granted Cipla accelerated approval to make and sell favipiravir in an effort to meet the "urgent and unmet" need for Covid-19 treatment options in the country, the company said. Indian drugmakers including Glenmark Pharmaceuticals Ltd are racing to supply generic.....

This article is no longer available in our repository.

There could be multiple reasons for this.